Degenerative Diseases of the Nervous System, Parkinson Disease
Adams & Victors Principles of Neurology, Chp 39, pg 1082, Ropper, A.H.,et al, 2014
Prolactinomas
NEJM 362:1219-1226, Klibanski,A., 2010
Ropinirole 24-Hour Prolonged Release: Randomized, Controlled Study in Advanced Parkinson Disease
Neurol 68:1108-1115, Pahwa,R.,et al, 2007
Acromegaly
NEJM 355:2558-2573, Melmed,S., 2006
A randomized,Double-blind,Placebo-Controlled Trial of Subcutaneously Injected Apomorphine for Parkinsonian Off-State Events
Arch Neurol 58:1385-1392, Dewey,R.B.,et al, 2001
Efficacy, Safety, and Tolerance of the Non-Ergoline Dopamine Agonist Pramipexole in the Treatment of Advanced Parkinson's Disease:A Double Blind, Placebo Controlled, Randomised, Multicentre Study
JNNP 66:436-441, Pinter,M.M.,et al, 1999
Chiasmal Herniation as a Complication of Bromocriptine Therapy
J Neuro-Ophthalmol 16:252-257, Taxel,P.,et al, 1996
Multictr Study of Cabergoline, A Long-Acting Dopamine Receptor Agonist, in PD Fluct Resp to Levodopa/Carbidopa
Neurol 43:1981-1984, Lieberman,A.,et al, 1993
Dopamine Agonist Treatment of Fluctuating Parkinsonisn
Arch Neurol 49:560-568, Ahlskog,J.E.,et al, 1992
Diagnosis and Management of Hormone-Secreting Pituitary Adenomas
NEJM 324:822-831, Klibanski,A.&Zervas,N.T., 1991
Subcutaneous Apomorphine in the Treatment of Parkinson's Disease
JNNP 53:96-101, Frankel,J.P.,et al, 1990
Nasogastric and Intravenous Infusions of (+) -4-propyl-9-hydroxynaphthoxazine (PHNO) in Parkinson's Disease
JNNP 53:102-105, 1990, Coleman,R.J.,et al, 1990
Subcutaneous Apomorphine in Parkinsonian On-Off Oscillations
Lancet 1:403-406, Stibe,C.M.H.,et al, 1988
Pergolide Mesylate & Idiopathic Parkinson Disease
Neurol 32:1175-1179, Tanner,C.M.,et al, 1982
Further Studies with Pergolide in Parkinson Disease
Neurol 32:1181-1184, Lieberman,A.N.,et al, 1982
Prolactin-Secreting Tumors & Hypogonadism in 22 Men
NEJM 299:847-852, Carter,J.N.,et al, 1978